Document is current
Any future updates will be listed below
-
Authors
Kragel, Philip A. http://orcid.org/0000-0001-9463-6381
Treadway, Michael T. http://orcid.org/0000-0002-5913-114X
Admon, Roee http://orcid.org/0000-0002-9886-5111
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Hahn, Evan C.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R00MH102355, P50MH119467, R37MH068376)
- License Information
-
More Information
Article History
Received: 27 August 2022
Accepted: 22 May 2023
First Online: 29 June 2023
Competing interests
: The authors declare the following competing interests: in the past 3 years M.T.T. has served as a paid consultant to Neumora Therapeutics (formerly BlackThorn Therapeutics) and Boehringer Ingelheim. Over the past 3 years, D.A.P. has received consulting fees from Albright Stonebridge Group, Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sunovion and Takeda; he has received honoraria from the Psychonomic Society and the American Psychological Association (for editorial work) and Alkermes; he has received research funding from the Brain and Behavior Research Foundation, the Dana Foundation, Millennium Pharmaceuticals, National Institute of Mental Health (NIMH) and Wellcome Leap; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics and Neuroscience Software. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. The remaining authors declare no competing interests.
